Biotech

Radiopharm commences First Phase 1 trialling in Australia

Wed 23 Mar 22, 2:30pm (AEST)
image

Stocks in article

rad
MktCap:
-

Share article

Key Points

  • Radiopharm’s share price was down -3.70% two hours out from the close today
  • The phase 1 therapeutic trial will target lung cancer

Radiopharm Theranostics (ASX:RAD) has entered a non-binding agreement with Australia’s largest provider of integrated cancer care GenesisCare to start its first Phase 1 trial locally.

Involving Radiopharm’s proprietary nanobody from its Nano-mAbs platform, the phase 1 therapeutic trial will target lung cancer.

This treatment has the potential to be the 'first in class' radiopharmaceutical therapy targeting PDL1.

The drug will specifically target the PDL1 expression in non-small cell lung cancer, which is the most common type of lung cancer.

Improving patient outcomes

“This is currently an area of high unmet need, and we are hopeful of bringing a first in class treatment to the market that will greatly improve patient outcomes,” said Radiopharm CEO, Riccardo Canevari.

“This is currently an area of high unmet need, and we are hopeful of bringing a first in class treatment to the market that will greatly improve patient outcomes.”

A leading provider of integrated oncology care globally, GenesisCare has than 440 locations in Australia, UK, USA and Spain.

Commenting on the today’s announced agreement, GenesisCare’s Kris Barooshian said:

“To date, radiopharmaceutical treatments have predominantly been utilised in the treatment of prostate cancer and neuroendocrine tumours, so it is exciting to be expanding the nuclear medicine treatment paradigm to new therapeutic areas.”

Radiopharm’s share price was down -3.70% two hours out from the close today.

image

Radiopharm traded lower today.

Written By

Market Index Corporate

Market Index helps small-cap ASX listed companies connect with a large audience of Australian investors through clear and concise articles on key developments. All coverage contains factual information only and should not be interpreted as an opinion or financial advice. Consider consulting a qualified financial adviser before making an investment decision.

Get the latest news and media direct to your inbox

Sign up FREE